Sophia Antipolis, France – June 7, 2011. Theralpha, a product development-oriented company, focusing on preclinical and clinical development of new pain therapeutics, today announced the appointment of Damian Marron to its board of directors.
“Damian Marron is a biotechnology industry leader, and we are delighted to welcome him”, commented David Dellamonica, CEO and founder of Theralpha. “His experience is relevant to Theralpha in many ways: clinical development, pain drugs expertise, business development, financing and scaling up companies. Damian is an extraordinary person with a great deal of talent in all aspects of building a business. His demonstrated success will be of significant value to Theralpha as we pursue preparation of series A funding and working on new collaborations around compounds or broader strategic partnerships, like that announced recently with Flamel Technologies. I know Damian will be a great mentor to me.” David Dellamonica added. “I am very excited to join the board of directors of Theralpha, an organization which already has an exciting pipeline of preclinical peptide therapeutics. Importantly, these compounds are designed to target the fundamental mechanisms of pain, with strong scientific and preclinical evidence and they are developed forhigh potential indications. I look forward to working with the Theralpha team to help realize their significant potential, which can be leveraged in transactions that will allow the company to aggressively advance ", commented Damian Marron
Damian Marron is the Chief Executive Officer of Trophos SA. Mr. Marron has over 20 years of international experience in the biotechnology and pharmaceutical industry, in particular in the fields of R&D and corporate development. He has raised over €200M in public and private equity, patient association funding and non- dilutive grants. He served as Executive Vice President of Corporate Development of Nicox SA from 2002 to 2008. Prior to this, he was Head of the European Development Business at 3M Pharmaceuticals between 1997 and 2002. From 1995 to 1997, Mr. Marron was responsible for the business in the UK for Orphan Europe; it specialized in the orphan drugs. From 1991 to 1995, he served with Rhône-Poulenc Rorer, initially as Senior Coordinator of Clinical research in oncology then as Director for the Clinical Operations within joint venture the Chugai-Rhone-Poulenc. From 1986 to 1991, he held the functions of Clinical Research Associate in the field of the central nervous system and of researcher in cellular biology at Glaxo. Mr. Marron obtained his honours degree in pharmacology from the University of Liverpool in 1985, and supplemented by research in the field of the monoclonal antibodies within the service of Radiation Oncology of the University.
About Theralpha
Theralpha SAS is a product development-oriented company, focusing on preclinical and clinical development of new pain therapeutics. Theralpha drug candidates originate from worldwide exclusive licenses from IPMC (Institut de Pharmacologie Moleculaire, CNRS, Sophia Antipolis, France) based on research made by Professor Michel Lazdunski and his team who have pioneered the discovery of peptides found in animal venoms that selectively inhibit Acid Sensing Ion Channels (ASICs) which are directly implicated in pain signal transmission. Theralpha is also developing an analgesic venom derived peptide generated at Protherapeutics, a National University of Singapore (NUS) spin-off, and licensed worldwide to Theralpha. To learn more about Theralpha, please visit www.theralpha.com
Contacts
Theralpha SAS
David Dellamonica CEO
david@theralpha.com
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
